Key Highlights
- Kenvue delivered Q1 adjusted EPS of $0.32, surpassing analyst projections of $0.26–$0.31
- Quarterly revenue totaled $3.91 billion, reflecting a 4.5% year-over-year increase and exceeding the $3.84 billion forecast
- The Skin Health and Beauty division drove performance with sales climbing 8.4%
- Kimberly-Clark’s $40 billion takeover remains scheduled for completion in H2 2026
- Forward-looking guidance was withheld given the ongoing merger transaction
Kenvue (KVUE) unveiled first-quarter financial performance on Thursday that exceeded analyst projections for both earnings and sales, sending shares higher by approximately 1.78% during trading.
The consumer healthcare firm delivered adjusted earnings of $0.32 per share, outperforming the consensus analyst forecast ranging from $0.26 to $0.31. Quarterly revenue totaled $3.91 billion for the period concluding March 29, representing a 4.5% increase from $3.74 billion in the corresponding quarter last year and surpassing the anticipated $3.84 billion.
Organic revenue advanced 0.7%, supported by 1.0% positive pricing impact, though partially counterbalanced by a 0.3% decrease in volume.
KVUE shares had declined 0.11% during pre-market activity before the earnings announcement, though the positive results helped restore investor confidence.
Chief Executive Kirk Perry emphasized that the organization achieved both net and organic revenue expansion for consecutive quarters, accompanied by year-over-year enhancements in gross margin, operating margin, and earnings per share.
Adjusted gross profit margin widened by 80 basis points to reach 60.8%, attributed to supply chain efficiencies and beneficial pricing strategies that mitigated inflationary pressures and tariff-related challenges. Adjusted operating income margin strengthened to 24.0% compared to 19.8% in the prior-year period.
Skin Health and Beauty Division Delivers Exceptional Growth
The Skin Health and Beauty category emerged as the top-performing segment, posting net sales growth of 8.4% to reach $1.06 billion. Major brands including Neutrogena and Aveeno generated strong consumer demand across international markets.
Self Care increased 1.9% while Essential Health advanced 4.9%. The Self Care segment faced headwinds from a subdued cold and flu season throughout key geographic regions.
Management indicated that its ongoing restructuring initiative is projected to generate pre-tax charges approaching $250 million throughout the current fiscal year.
Kimberly-Clark Acquisition Influences Future Planning
Kenvue declined to provide forward-looking guidance citing the anticipated $40 billion takeover by Kimberly-Clark, which remains targeted for completion during the second half of 2026, pending international regulatory clearances.
Kimberly-Clark shares appreciated approximately 2.05% during the session, with investors interpreting the earnings positively for the acquiring company.
RBC Capital Markets analyst Nik Modi characterized the results as encouraging for Kimberly-Clark, stating “Kenvue’s fundamentals seem to be stabilizing.” He observed that near-term share price movement will probably be influenced more significantly by transaction timing and legal developments rather than core operational performance.
